// App-Quantinova.ai

1009 : Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

Researchers

Presenter

  • Sylvia Adams

Principal Investigators

  • Jennifer Robinson Diamond

  • Erika Paige Hamilton

  • Paula Raffin Pohlmann

  • Sara M. Tolaney

  • Luciana Molinero

  • Xian He

  • Daniel Waterkamp

  • Roel Peter Funke

  • John D. Powderly

Medical Centers

  • New York University Cancer Institute, New York, NY

  • University of Colorado Cancer Center, Aurora, CO

  • Sarah Cannon Research Institute/Tennessee Oncology, Brentwood, TN

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Dana-Farber Cancer Institute, Boston, MA

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Carolina BioOncology Institute, Huntersville, NC

Locations

  • United States

  • Switzerland

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01633970

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved